Researchers analyzed 177,919 residual test specimens from commercial laboratories nationwide. Samples were obtained during four separate collection periods between July 27 and Sept. 24.
Researchers’ estimates of antibody prevalence ranged from less than 1 percent to 23 percent depending on the city or jurisdiction. In most areas, less than 10 percent of the population had detectable antibodies as of September.
Overall, the Northeast had the highest antibody levels, though estimates varied widely by jurisdiction. New York also had the highest percentage of people with antibodies at 23.3 percent during the first specimen collection period.
To view the full study, click here.
More articles on public health:
COVID-19 death rates by state: Nov. 25
22 states where COVID-19 is spreading fastest, slowest: Nov. 25
CDC may shorten 14-day COVID-19 quarantine recommendation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
